Navigation Links
Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies
Date:11/27/2012

ngs us one step closer towards achieving this objective."

The Phase 2 study is expected to enroll at least 45 adult patients undergoing dUCBT for the treatment of hematologic malignancies.  Patients will be randomized, with a ratio of 2:1, to receive either ProHema plus an unmanipulated cord blood unit or two unmanipulated cord blood units.  The study will evaluate time to neutrophil and platelet recovery, incidence of serious infections and graft-versus-host disease, 100-day mortality and relative dominance of ProHema over the unmanipulated cord in contributing to reconstitution.  Results are expected in 2013.

"The preclinical and clinical data obtained to date suggest that ProHema may address several of the unmet medical needs in the evolving field of hematopoietic stem cell transplantation," said Steven Devine, M.D., Professor of Medicine and Program Director of the Blood and Marrow Transplant Program at the Ohio State University and a principal investigator of the Phase 2 clinical study.  "While further investigation is required, an intervention that enables early and durable reconstitution of the best-HLA-matched cord blood unit has the potential to improve patient outcomes and substantially enhance the therapeutic value proposition of cord blood transplant."

About ProHema

ProHema is an innovative cord blood-derived cell therapy containing pharmacologically-modulated hematopoietic stem cells (HSCs).  ProHema is produced through a proprietary, two-hour, ex vivo cell modulation process that results in rapid activation of key biological pathways involved in homing, proliferation and survival of HSCs.  In preclinical testing, ProHema has demonstrated the potential to accelerate engraftment and to drive durable hematopoietic reconstitution, without the need for multi-week expansion protocols.  In an initial Phase 1b study in adult patients with hematologic malignancies undergoing double umbilical
'/>"/>

SOURCE Fate Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
2. MabVax Therapeutics Closes $5.25 Million Financing with Numoda Capital Innovations, Burrill Capital Fund IV, and RTP Venture Fund
3. Cystic Fibrosis Foundation Therapeutics Announces $58 Million CF Drug Discovery Agreement with Pfizer
4. Echo Therapeutics Hires Daniel Sunday as Vice President of Manufacturing and Global Supply Chain
5. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
6. Echo Therapeutics Chosen to Present at the 12th Annual Diabetes Technology Meeting
7. Immunomic Therapeutics Begins Phase I Japanese Red Cedar JRC-LAMP-Vax Vaccine Safety Study
8. Stemline Therapeutics Lead Clinical Candidate SL-401 Induces a Complete Response in a Patient with a Drug-Refractory Plasmacytoid Dendritic Cell Neoplasm
9. Echo Therapeutics Announces Third Quarter 2012 Financial Results
10. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
11. Particle Sciences Develops Novel Ocular Formulation for Eyeon Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)...  Decision Resources Group finds that the market for interventional ... remain relatively stagnant at a value of around $80 million ... intervention (PCI) volumes are growing faster in Canada ... the United States and Europe ... increase in penetration of PCI procedures relative to coronary artery ...
(Date:7/22/2014)... According to a new ... (Technology Types - Near infrared (NIR) spectroscopy, Raman spectroscopy and ... Size, Share, Growth, Trends and Forecast, 2013 - 2019," the ... is expected to grow at a CAGR of 7.4% from ... was the largest contributor to global process spectroscopy market ...
(Date:7/22/2014)... , July 22, 2014  Eyeon Therapeutics has received ... treatment based on a charged hydrophilic polymer developed at ... has been shown to be safe and effective in ... MD, CEO states, "This first set of claims around ... way to moving this technology into the commercial phase.  ...
Breaking Medicine Technology:The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 2The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 3Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 2Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 3Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 4Particle Sciences and Eyeon Therapeutics Receive Patent on Novel Dry Eye Technology 2
... 12, 2011 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... on August 29, 2011, as Vice President, Finance and Chief ... Arena for over 13 years before departing in March to ... a valuable leader who has been a key contributor to ...
... 2011 5 modules - 2 weeks - ... to announce that the Stability Testing Online Training Course is proving ... ,The secret behind the Stability testing Online Training Course ... is its user-friendly format which allows flexible and interactive high standard, ...
Cached Medicine Technology:Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer 2Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer 3Stability Testing Course is Taking the Online Training Format by Storm! 2
(Date:7/22/2014)... 22, 2014 A Florida woman has ... that alleges the death of her husband was the ... thinner, Bernstein Liebhard LLP reports. According to her complaint, ... for the Southern District of Florida on June 23rd, ... suffered a subdural hemorrhage the following June. Despite emergency ...
(Date:7/22/2014)... HealthDay Reporter TUESDAY, July ... pregnancy may be more likely to have children with asthma ... that, compared with children born from mothers of normal weight, ... up to 20 to 30 percent higher odds of asthma," ... pediatrics at Children,s Hospital of Pittsburgh. Forno,s team also ...
(Date:7/22/2014)... 2014) The American Society of Hematology (ASH) will ... of Medicine, and Robert P. Hebbel, MD, of the ... Beutler Lecture and Prize for their significant research advances ... Ernest Beutler Lecture, named for the late Ernest Beutler, ... more than 50 years, is a two-part lectureship that ...
(Date:7/22/2014)... of the Clean Plate Club you eat pretty much ... A new Cornell University study shows that the average ... his or her plate. "If you put it ... Wansink Ph.D., author of the forthcoming book, Slim by Design, ... Brand Lab. , Wansink and co-author Katherine Abowd Johnson analyzed ...
(Date:7/22/2014)... disease, Dr. Ross Feldman says women are often in the ... men,s-only disease, however, data has shown that post-menopausal women are ... are less likely to be adequately diagnosed and treated. New ... British Journal of Clinical Pharmacology brings to light ... to identify which women are more prone to heart disease. ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 3Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 2Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 2Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 4Health News:Gene variant identified as a heart disease risk factor for women 2
... February issue of PNAS that understanding and treating cholesterol-related ... discovery of a receptor in the cells of mice ... during a study of cerebrotendinous xanthomatosis (CTX), a rare ... They said that Pregnane X receptor (PXR)// is present ...
... curvature of the spine diagnosed after the age ten, ... to earlier belief that the condition increases mortality rates ... related to the curvature. Researchers from the University of ... with LIS appear to experience only little physical// impairment ...
... to be launched by researchers from the UK and Netherlands ... with cancer. The research will be led by Dr. Julian ... Dr. René Bernards of the Netherlands Cancer Institute. This research ... and will have scientists looking at nearly 10,000 genes, inactivating ...
... journal, Cancer Cell reported that scientists have discovered why some ... others. Researchers have found that high levels of a specific ... drugs such as Taxol, which are used to treat a ... the// researchers focused on a molecule called AURORA-A which is ...
... has shown that those who smoke face the highest ... However, researchers added that more studies are needed before ... of cross-sectional data obtained from the US National Household ... from 1994 to 1996) was conducted. A total// of ...
... from the Department of Human Services at the University ... elevated levels of abdominal visceral fat are associated with ... was also found to be a primary determinant in ... investigators assessed// plasma lipids and lipoproteins and their relationships ...
Cached Medicine News:Health News:Cancer gene mystery to be cracked! 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: